The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
| Title |
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, February 2017
|
| DOI | 10.2147/tcrm.s104343 |
| Pubmed ID | |
| Authors |
Alexander D Le, Saeed K Alzghari, Gary W Jean, Ninh M La-Beck |
| Abstract |
While the initial treatment of non-small cell lung cancer (NSCLC) usually relies on surgical resection followed by systemic cytotoxic chemotherapy and/or radiation therapy, recent advances in understanding of NSCLC biology and immunology have spurred the development of numerous targeted therapies. In particular, a class of immune modulatory drugs targeting the immune checkpoint pathways has demonstrated remarkable durable remissions in a select minority of advanced NSCLC patients, potentially heralding the elusive "cancer cure". This review focuses on the clinical evidence for one of these agents, nivolumab, and clarifies the role of this drug in the context of the other targeted therapies currently available for the treatment of NSCLC. We also discuss the impact of nivolumab on patient quality of life and health economics. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 84 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 17% |
| Student > Master | 14 | 17% |
| Student > Bachelor | 11 | 13% |
| Student > Ph. D. Student | 8 | 10% |
| Student > Postgraduate | 6 | 7% |
| Other | 10 | 12% |
| Unknown | 21 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 13% |
| Biochemistry, Genetics and Molecular Biology | 8 | 10% |
| Nursing and Health Professions | 6 | 7% |
| Immunology and Microbiology | 2 | 2% |
| Other | 8 | 10% |
| Unknown | 23 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2019.
All research outputs
#3,416,577
of 25,382,440 outputs
Outputs from Therapeutics and Clinical Risk Management
#167
of 1,323 outputs
Outputs of similar age
#66,626
of 424,972 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#4
of 19 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 424,972 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.